CA2531832C - Powdery formulations for inhalation, containing a novel anticholinergic agent - Google Patents
Powdery formulations for inhalation, containing a novel anticholinergic agent Download PDFInfo
- Publication number
- CA2531832C CA2531832C CA2531832A CA2531832A CA2531832C CA 2531832 C CA2531832 C CA 2531832C CA 2531832 A CA2531832 A CA 2531832A CA 2531832 A CA2531832 A CA 2531832A CA 2531832 C CA2531832 C CA 2531832C
- Authority
- CA
- Canada
- Prior art keywords
- excipient
- inhalable
- active substance
- inhalable powder
- powder according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title abstract description 23
- 238000009472 formulation Methods 0.000 title abstract description 10
- 239000000812 cholinergic antagonist Substances 0.000 title abstract description 4
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title abstract description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 10
- 150000001450 anions Chemical class 0.000 claims abstract description 9
- 208000006673 asthma Diseases 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims description 87
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 65
- 239000013543 active substance Substances 0.000 claims description 50
- 239000002775 capsule Substances 0.000 claims description 34
- 239000002245 particle Substances 0.000 claims description 34
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 24
- 239000000463 material Substances 0.000 claims description 15
- 230000000241 respiratory effect Effects 0.000 claims description 8
- 150000001768 cations Chemical class 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 229920000858 Cyclodextrin Polymers 0.000 claims description 6
- 229920003023 plastic Polymers 0.000 claims description 6
- 239000004033 plastic Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims description 3
- 150000002016 disaccharides Chemical class 0.000 claims description 3
- 150000002772 monosaccharides Chemical class 0.000 claims description 3
- 150000005846 sugar alcohols Polymers 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- 229940097362 cyclodextrins Drugs 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 150000002482 oligosaccharides Polymers 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 20
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 208000018569 Respiratory Tract disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 238000000227 grinding Methods 0.000 description 17
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 229960001021 lactose monohydrate Drugs 0.000 description 11
- 238000002156 mixing Methods 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- -1 a-cyclodextrin Chemical class 0.000 description 9
- 229960001375 lactose Drugs 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000007789 gas Substances 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000001828 Gelatine Substances 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 239000003708 ampul Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229960000673 dextrose monohydrate Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NMGODFWGUBLTTA-UHFFFAOYSA-N 3-amino-1h-quinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)N(N)C(=O)NC2=C1 NMGODFWGUBLTTA-UHFFFAOYSA-N 0.000 description 1
- 238000004438 BET method Methods 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- FIMXSEMBHGTNKT-UHFFFAOYSA-N Scopine Natural products CN1C2CC(O)CC1C1C2O1 FIMXSEMBHGTNKT-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 150000002597 lactoses Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- FIMXSEMBHGTNKT-RZVDLVGDSA-N scopine Chemical compound C([C@@H]1N2C)[C@H](O)C[C@@H]2[C@@H]2[C@H]1O2 FIMXSEMBHGTNKT-RZVDLVGDSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention relates to powdery formulations for inhalation, containing an anticholinergic agent of formula (I), wherein X represents an anion which can have meanings cited in the description and in the claims, a method for the production thereof and the use thereof in the production of a medicament for treating respiratory tract diseases, especially for treating COPD (chronic obstructive pulmonary disease) and asthma.
Description
POWDERY FORMULATIONS FOR INHALATION, CONTAINING A NOVEL
ANTICHOLINERGIC AGENT
The invention relates to powder formulations for inhalation, containing as sole active substance an anticholinergic of formula 1 Me\+/Me -X
N
O H
O O
Me \ I \ f wherein X - may denote an anion having the meanings described herein, processes for preparing them and their use for preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.
Background to the invention The compounds of formula 1 are known from WO 02/32899. They have valuable pharmacological properties and can provide therapeutic benefit as highly effective anticholinergics in the treatment of respiratory complaints, particularly in the treatment of inflammatory and/or obstructive diseases of the respiratory tract, particularly for treating asthma or COPD (chronic obstructive pulmonary disease).
When treating the above diseases it is convenient to administer the active substance by inhalation. In addition to the administration by inhalation of broncholytically active compounds in the form of metered aerosols and inhalable solutions the administration of inhalable powders containing active substance is also of particular importance.
In the case of active substances with a particularly high efficacy, only small amounts of the active substance are needed per single dose to achieve the therapeutically desired effect. In such cases the active substance has to be diluted with suitable excipients to prepare the inhalable powder. Because of the large amount of excipient, the properties of the inhalable powder are critically influenced by the choice of excipient. When choosing the excipient its particle size is particularly important. As a rule, the finer the excipient, the poorer its flow properties. However, good flow properties are a prerequisite for highly accurate metering when packing and dividing up the individual doses of preparation, e.g.
when producing capsules (inhalettes) for powder inhalation or when the patient is metering the individual dose before using a multi-dose inhaler. Moreover, the particle size of the excipient is very important for the emptying characteristics of capsules when used in an inhaler. It has also been found that the particle size of the excipient has a considerable influence on the proportion of active substance in the inhalable powder which is delivered for inhalation. The term inhalable proportion of active substance refers to the particles of the inhalable powder which are conveyed deep into the branches of the lungs when inhaled with a breath. The particle size required for this is between 1 and 10 m, preferably less than 6 m.
The aim of the invention is to prepare an inhalable powder containing the active substance of formula 1 which, while being accurately metered (in terms of the quantity of active substance released and delivered to the lungs on each inhalation process) with only slight variations between batches, enables the active substance to be administered in a large inhalable proportion. A further aim of the present invention is to prepare an inhalable powder containing the active substance of formula 1 which ensures good emptying characteristics of the capsules, if the powder is administered by means of powder-filled capsules.
A further aim of the invention is to provide an inhalable powder which is characterised by a high degree of homogeneity of the powder mixture and minimal fluctuations in the dispersion characteristics from one batch of powder to the next.
The homogeneity of the powder mixture and minor fluctuations in the dispersion properties are crucial in ensuring that the inhalable proportion of active substance is released reproducibly in constant amounts and hence with the lowest possible variability. Accordingly, the present invention also sets out to prepare an inhalable powder which allows the inhalable proportion of active substance to be administered with the lowest possible variability.
The characteristics of emptying from the powder reservoir (the container from which the inhalable powder containing the active substance is released for inhalation) play an important part, not exclusively, but especially in the administration of inhalable powders using powder-filled capsules. If only a small amount of the powder formulation is released from the powder reservoir as a result of minimal or poor emptying characteristics, significant amounts of the inhalable powder containing the active substance are left in the powder reservoir (e.g.
the capsule) and are unavailable to the patient for therapeutic use. The result of this is that the dosage of active substance in the powder mixture has to be increased so that the quantity of active substance delivered is sufficient to produce the desired therapeutic effect.
Against this background the present invention further sets out to provide an inhalable powder which is also characterised by very good emptying characteristics.
Detailed description of the invention It was found that, surprisingly, the objectives outlined above can be achieved by means of the powdered preparations for inhalation (inhalable powders) according to the invention described hereinafter.
Accordingly, the present invention relates to inhalable powders containing as sole active substance a compound of formula .1 Meg+Me -N X
O H
O O
Me wherein X- denotes a pharmaceutically acceptable anion, mixed with a physiologically acceptable excipient, characterised in that the excipient has an average particle size of 10 - 50 m.
By the average particle size is meant here the 50% value of the volume distribution measured using a laser diffractometer by the dry dispersion method.
ANTICHOLINERGIC AGENT
The invention relates to powder formulations for inhalation, containing as sole active substance an anticholinergic of formula 1 Me\+/Me -X
N
O H
O O
Me \ I \ f wherein X - may denote an anion having the meanings described herein, processes for preparing them and their use for preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.
Background to the invention The compounds of formula 1 are known from WO 02/32899. They have valuable pharmacological properties and can provide therapeutic benefit as highly effective anticholinergics in the treatment of respiratory complaints, particularly in the treatment of inflammatory and/or obstructive diseases of the respiratory tract, particularly for treating asthma or COPD (chronic obstructive pulmonary disease).
When treating the above diseases it is convenient to administer the active substance by inhalation. In addition to the administration by inhalation of broncholytically active compounds in the form of metered aerosols and inhalable solutions the administration of inhalable powders containing active substance is also of particular importance.
In the case of active substances with a particularly high efficacy, only small amounts of the active substance are needed per single dose to achieve the therapeutically desired effect. In such cases the active substance has to be diluted with suitable excipients to prepare the inhalable powder. Because of the large amount of excipient, the properties of the inhalable powder are critically influenced by the choice of excipient. When choosing the excipient its particle size is particularly important. As a rule, the finer the excipient, the poorer its flow properties. However, good flow properties are a prerequisite for highly accurate metering when packing and dividing up the individual doses of preparation, e.g.
when producing capsules (inhalettes) for powder inhalation or when the patient is metering the individual dose before using a multi-dose inhaler. Moreover, the particle size of the excipient is very important for the emptying characteristics of capsules when used in an inhaler. It has also been found that the particle size of the excipient has a considerable influence on the proportion of active substance in the inhalable powder which is delivered for inhalation. The term inhalable proportion of active substance refers to the particles of the inhalable powder which are conveyed deep into the branches of the lungs when inhaled with a breath. The particle size required for this is between 1 and 10 m, preferably less than 6 m.
The aim of the invention is to prepare an inhalable powder containing the active substance of formula 1 which, while being accurately metered (in terms of the quantity of active substance released and delivered to the lungs on each inhalation process) with only slight variations between batches, enables the active substance to be administered in a large inhalable proportion. A further aim of the present invention is to prepare an inhalable powder containing the active substance of formula 1 which ensures good emptying characteristics of the capsules, if the powder is administered by means of powder-filled capsules.
A further aim of the invention is to provide an inhalable powder which is characterised by a high degree of homogeneity of the powder mixture and minimal fluctuations in the dispersion characteristics from one batch of powder to the next.
The homogeneity of the powder mixture and minor fluctuations in the dispersion properties are crucial in ensuring that the inhalable proportion of active substance is released reproducibly in constant amounts and hence with the lowest possible variability. Accordingly, the present invention also sets out to prepare an inhalable powder which allows the inhalable proportion of active substance to be administered with the lowest possible variability.
The characteristics of emptying from the powder reservoir (the container from which the inhalable powder containing the active substance is released for inhalation) play an important part, not exclusively, but especially in the administration of inhalable powders using powder-filled capsules. If only a small amount of the powder formulation is released from the powder reservoir as a result of minimal or poor emptying characteristics, significant amounts of the inhalable powder containing the active substance are left in the powder reservoir (e.g.
the capsule) and are unavailable to the patient for therapeutic use. The result of this is that the dosage of active substance in the powder mixture has to be increased so that the quantity of active substance delivered is sufficient to produce the desired therapeutic effect.
Against this background the present invention further sets out to provide an inhalable powder which is also characterised by very good emptying characteristics.
Detailed description of the invention It was found that, surprisingly, the objectives outlined above can be achieved by means of the powdered preparations for inhalation (inhalable powders) according to the invention described hereinafter.
Accordingly, the present invention relates to inhalable powders containing as sole active substance a compound of formula .1 Meg+Me -N X
O H
O O
Me wherein X- denotes a pharmaceutically acceptable anion, mixed with a physiologically acceptable excipient, characterised in that the excipient has an average particle size of 10 - 50 m.
By the average particle size is meant here the 50% value of the volume distribution measured using a laser diffractometer by the dry dispersion method.
Preferred inhalable powders are those which contain as their sole active ingredient a compound of formula 1 wherein the anion X" is selected from the group consisting of chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate.
Preferably salts of formula 1 are used wherein X- denotes an anion selected from among chloride, bromide, 4-toluenesulphonate and methanesulphonate.
Particularly preferred within the scope of the present invention are those formulations which contain the compound of formula 1 wherein X" denotes bromide as their sole active substance.
References to the compound of formula 1 within the scope of the present invention always include all possible amorphous and crystalline modifications of this compound. References to the compound of formula I within the scope of the present invention also include all possible solvates and hydrates which may be formed by this compound. In an exemplary embodiment, the hydrate of the compound is provided.
Any reference to the compound V within the scope of the present invention is to be regarded as a reference to the pharmacologically active cation of the formula shown below contained in the salts 1 Meg+,Me N
O Fi O O
Me If.
4a The content of active substance in the inhalable powders according to the invention is in the range from 0.0008 to 33%, based on the pharmacologically active cation 1'.
Within the scope of the present invention amounts given in percent are always to be interpreted as percent by weight unless specifically stated to the contrary.
Preferably salts of formula 1 are used wherein X- denotes an anion selected from among chloride, bromide, 4-toluenesulphonate and methanesulphonate.
Particularly preferred within the scope of the present invention are those formulations which contain the compound of formula 1 wherein X" denotes bromide as their sole active substance.
References to the compound of formula 1 within the scope of the present invention always include all possible amorphous and crystalline modifications of this compound. References to the compound of formula I within the scope of the present invention also include all possible solvates and hydrates which may be formed by this compound. In an exemplary embodiment, the hydrate of the compound is provided.
Any reference to the compound V within the scope of the present invention is to be regarded as a reference to the pharmacologically active cation of the formula shown below contained in the salts 1 Meg+,Me N
O Fi O O
Me If.
4a The content of active substance in the inhalable powders according to the invention is in the range from 0.0008 to 33%, based on the pharmacologically active cation 1'.
Within the scope of the present invention amounts given in percent are always to be interpreted as percent by weight unless specifically stated to the contrary.
Inhalable powders which contain 0.008 to 20.6% 1' are preferred according to the invention. Particularly preferred inhalable powders contain 1' in an amount of about 0.025 to 9.9%, preferably 0.05 to 6.6%, particularly preferably 0.07 to 3.3%.
Lastly, inhalable powders which contain about 0.08 to 2.5% of cation 1' are of particular importance according to the invention.
The content of the compounds of formula 1 (= cation 1' plus anion X-) can easily be calculated from the content of pharmacologically active cation 1' depending on the choice of the corresponding anion X-. If for example X- denotes the bromide anion which is particularly preferred according to the invention, the inhalable powders according to the invention may contain between 0.001 and 40 %, preferably 0.01 to 25 % of compound 1 (in form of the bromide). Of particular interest according to the invention are inhalable powders which contain about 0.03 to 12%, preferably 0.06 to 8%, particularly preferably 0.08 to 4% of compound in the form of the bromide. Of particular importance according to the invention are inhalable powders which contain about 0.1 to 3% of the compound of formula 1 (in the form of the bromide).
The formulations according to the invention contain the compounds of formula 1 as sole active substance. Pharmaceutical formulations which contain other active substances in addition to a compound of formula 1 are not the subject of this invention.
In particularly preferred inhalable powders the excipient is characterised by an average particle size of 12 to 35 gm, particularly preferably from 13 to 30 m.
Particularly preferred embodiments of the invention are further characterised in that the excipient has a 10% fine content of from 0.5 to 6 m. The 10% fine content in this instance refers to the 10% value of the volume distribution measured using a laser diffractometer by the dry dispersion method.
Particularly preferred according to. the invention are those inhalable powders wherein the 10% fine content is about 1 to 4 m, preferably about 1.5 to 3 m.
Also particularly preferred are those inhalable powders wherein the excipient has a specific surface area of 0.1 to 2 m2/g. By specific surface area is meant, for the purposes of the invention, the mass-specific powder surface area, calculated from the N2 absorption isotherm which is observed at the boiling point of liquid nitrogen (method of Brunauer, Emmett and Teller).
Also preferred according to the invention are those inhalable powders wherein the excipient has a specific surface area of between 0.2 and 1.5 m2/g, preferably between 0.3 and 1.0 m2/g.
The excipients used for the purposes of the present invention are preferably prepared by suitable grinding and/or screening by common methods known in the art. The excipients used according to the invention may possibly also be mixtures of excipients obtained by mixing together excipient fractions of different mean particle sizes.
Examples of physiologically acceptable excipients which may be used to prepare the inhalable powders used for the inhalettes according to the invention include, for example, monosaccharides (e.g. glucose, fructose, arabinose), disaccharides (e.g.
lactose, saccharose, maltose, trehalose), oligo- and polysaccharides (e.g.
dextranes, dextrins, maltodextrin, starch, cellulose), polyalcohols (e.g. sorbitol, mannitol, xylitol), cyclodextrins (e.g. a-cyclodextrin, (3-cyclodextrin, x-cyclodextrin, methyl-(3-cyclodextrin, hydroxypropyl-j3-cyclodextrin), amino acids (e.g. arginine hydrochloride) or salts (e.g. sodium chloride, calcium carbonate). Preferably, mono- or disaccharides are used, while the use of lactose or glucose is preferred, particularly, but not exclusively, in the form of their hydrates. For the purposes of the invention, lactose is the particularly preferred excipient, while lactose monohydrate is most particularly preferred.
Preferably, excipients of high crystallinity are used for the powder formulations according to the invention. This crystallinity can be assessed by means of the enthalpy released as the excipient is dissolved (solution enthalpy). In the case of the excipient lactose monohydrate, which is most preferably used according to the invention, it is preferable to use lactose which is characterised by a solution enthalpy of > 45 J/g, preferably > 50 J/g, particularly preferably > 52 J/g.
The inhalable powders according to the invention are characterised, in accordance with the problem on which the invention is based, by a high degree of homogeneity in the sense of the accuracy of single doses. This is in the region of < 8 % , preferably < 6 % , most preferably < 4 `Vo.
Lastly, inhalable powders which contain about 0.08 to 2.5% of cation 1' are of particular importance according to the invention.
The content of the compounds of formula 1 (= cation 1' plus anion X-) can easily be calculated from the content of pharmacologically active cation 1' depending on the choice of the corresponding anion X-. If for example X- denotes the bromide anion which is particularly preferred according to the invention, the inhalable powders according to the invention may contain between 0.001 and 40 %, preferably 0.01 to 25 % of compound 1 (in form of the bromide). Of particular interest according to the invention are inhalable powders which contain about 0.03 to 12%, preferably 0.06 to 8%, particularly preferably 0.08 to 4% of compound in the form of the bromide. Of particular importance according to the invention are inhalable powders which contain about 0.1 to 3% of the compound of formula 1 (in the form of the bromide).
The formulations according to the invention contain the compounds of formula 1 as sole active substance. Pharmaceutical formulations which contain other active substances in addition to a compound of formula 1 are not the subject of this invention.
In particularly preferred inhalable powders the excipient is characterised by an average particle size of 12 to 35 gm, particularly preferably from 13 to 30 m.
Particularly preferred embodiments of the invention are further characterised in that the excipient has a 10% fine content of from 0.5 to 6 m. The 10% fine content in this instance refers to the 10% value of the volume distribution measured using a laser diffractometer by the dry dispersion method.
Particularly preferred according to. the invention are those inhalable powders wherein the 10% fine content is about 1 to 4 m, preferably about 1.5 to 3 m.
Also particularly preferred are those inhalable powders wherein the excipient has a specific surface area of 0.1 to 2 m2/g. By specific surface area is meant, for the purposes of the invention, the mass-specific powder surface area, calculated from the N2 absorption isotherm which is observed at the boiling point of liquid nitrogen (method of Brunauer, Emmett and Teller).
Also preferred according to the invention are those inhalable powders wherein the excipient has a specific surface area of between 0.2 and 1.5 m2/g, preferably between 0.3 and 1.0 m2/g.
The excipients used for the purposes of the present invention are preferably prepared by suitable grinding and/or screening by common methods known in the art. The excipients used according to the invention may possibly also be mixtures of excipients obtained by mixing together excipient fractions of different mean particle sizes.
Examples of physiologically acceptable excipients which may be used to prepare the inhalable powders used for the inhalettes according to the invention include, for example, monosaccharides (e.g. glucose, fructose, arabinose), disaccharides (e.g.
lactose, saccharose, maltose, trehalose), oligo- and polysaccharides (e.g.
dextranes, dextrins, maltodextrin, starch, cellulose), polyalcohols (e.g. sorbitol, mannitol, xylitol), cyclodextrins (e.g. a-cyclodextrin, (3-cyclodextrin, x-cyclodextrin, methyl-(3-cyclodextrin, hydroxypropyl-j3-cyclodextrin), amino acids (e.g. arginine hydrochloride) or salts (e.g. sodium chloride, calcium carbonate). Preferably, mono- or disaccharides are used, while the use of lactose or glucose is preferred, particularly, but not exclusively, in the form of their hydrates. For the purposes of the invention, lactose is the particularly preferred excipient, while lactose monohydrate is most particularly preferred.
Preferably, excipients of high crystallinity are used for the powder formulations according to the invention. This crystallinity can be assessed by means of the enthalpy released as the excipient is dissolved (solution enthalpy). In the case of the excipient lactose monohydrate, which is most preferably used according to the invention, it is preferable to use lactose which is characterised by a solution enthalpy of > 45 J/g, preferably > 50 J/g, particularly preferably > 52 J/g.
The inhalable powders according to the invention are characterised, in accordance with the problem on which the invention is based, by a high degree of homogeneity in the sense of the accuracy of single doses. This is in the region of < 8 % , preferably < 6 % , most preferably < 4 `Vo.
After the starting materials have been weighed in the inhalable powders are prepared from the excipient and the active substance using methods known in the art. Reference may be made to the disclosure of WO 02/30390, for example. The inhalable powders according to the invention may accordingly be obtained by the method described below, for example. In the preparation methods described hereinafter the components are used in the proportions by weight described in the above-mentioned compositions of the inhalable powders.
First, the excipient and the active substance are placed in a suitable mixing container. The active substance used has an average particle size of 0.5 to 10 gm, preferably 1 to 6 gm, most preferably 2 to 5 gm. The excipient and the active substance are preferably added using a sieve or a granulating sieve with a mesh size of 0.1 to 2 mm, preferably 0.3 to 1 mm, most preferably 0.3 to 0.6 mm.
Preferably, the excipient is put in first and then the active substance is added to the mixing container. During this mixing process the two components are preferably added in batches. It is particularly preferred to sieve in the two components in alternate layers. The mixing of the excipient with the active substance may take place while the two components are still being added. Preferably, however, mixing is only done once the two components have been sieved in layer by layer.
If after being chemically prepared the active substance used in the process described above is not already obtainable in a crystalline form with the particle sizes mentioned earlier, it can be ground up into the particle sizes which conform to the above-mentioned parameters (so-called micronising).
The micronising process may be carried out using conventional mills.
Preferably, the micronisation is carried out with the exclusion of moisture, more preferably, using a corresponding inert gas such as nitrogen, for example. It has proved particularly preferable to use air jet mills in which the material is comminuted by the impact of the particles on one another and on the walls of the grinding container. According to the invention, nitrogen is preferably used as the grinding gas. The material for grinding is conveyed by the grinding gas under specific pressures (grinding pressure). Within the scope of the present invention, the grinding pressure is usually set to a value between about 2 and 8 bar, preferably between about 3 and 7 bar, most preferably between about 3.5 and 6.5 bar. The material for grinding is fed into the air jet mill by means of the feed gas under specific pressures (feed pressure). Within the scope of the present invention a feed pressure of between about 2 and 8 bar, preferably between about 3 and 7 bar and most preferably between about 3.5 and 6 bar has proved satisfactory. The feed gas used is also preferably an inert gas, most preferably nitrogen again. The material to be ground (crystalline compound of formula 1) may be fed in at a rate of about 35 g/min, preferably at about 10-30 g/min.
For example, without restricting the subject of the invention thereto, the following apparatus has proved suitable as a possible embodiment of an air jet mill: a 2-inch Microniser with grinding ring, 0.8 mm bore, made by Messrs Sturtevant Inc., Circuit Street, Hanover, MA 02239, USA. Using this apparatus, the grinding process is preferably carried out with the following grinding parameters:
grinding pressure: about 4.5 - 6.5 bar; feed pressure: about 4.5 - 6.5 bar; supply of grinding material: about 17 - 21 g/min.
It may optionally be advantageous to add a finer excipient fraction with an average particle size of 1 to 9 m to the inhalable powders according to the invention.
Such inhalable powders which contain in addition to the active substance of formula I an excipient mixture which comprises, in addition to the excipient with an average particle size of 10 - 50 m mentioned hereinbefore, a specifically added excipient fraction with an average particle size of 1 - 9 m, are preferably prepared by first mixing the two excipient fractions and then adding the active substance to this excipient mixture. Suitable processes for preparing active substance formulations of this kind are known in the art (e.g. WO 02/30390, WO 03/017970, WO
03/017979).
If excipient mixtures of coarser and finer excipient fractions are used, the proportion of finer excipient in the total quantity of excipient is preferably 1 to 20%.
If excipient mixtures of coarser and finer excipient fractions are used, the coarser excipient fraction preferably has the above-mentioned properties in terms of mean particle size, specific surface area or crystallinity, whereas the finer excipient fraction mixed therewith is preferably characterised by an average particle size of from 2 to 8 m, particularly preferably from 3 to 7 m. Furthermore, the proportion of fine excipient fraction in the total quantity of excipient in inhalable powders of this kind which may be used is preferably 3 to 15%, particularly preferably 5 to 10%.
The present invention also relates to the use of the inhalable powders according to the invention for preparing a pharmaceutical composition for the treatment von respiratory complaints, particularly for the treatment of COPD and/or asthma.
First, the excipient and the active substance are placed in a suitable mixing container. The active substance used has an average particle size of 0.5 to 10 gm, preferably 1 to 6 gm, most preferably 2 to 5 gm. The excipient and the active substance are preferably added using a sieve or a granulating sieve with a mesh size of 0.1 to 2 mm, preferably 0.3 to 1 mm, most preferably 0.3 to 0.6 mm.
Preferably, the excipient is put in first and then the active substance is added to the mixing container. During this mixing process the two components are preferably added in batches. It is particularly preferred to sieve in the two components in alternate layers. The mixing of the excipient with the active substance may take place while the two components are still being added. Preferably, however, mixing is only done once the two components have been sieved in layer by layer.
If after being chemically prepared the active substance used in the process described above is not already obtainable in a crystalline form with the particle sizes mentioned earlier, it can be ground up into the particle sizes which conform to the above-mentioned parameters (so-called micronising).
The micronising process may be carried out using conventional mills.
Preferably, the micronisation is carried out with the exclusion of moisture, more preferably, using a corresponding inert gas such as nitrogen, for example. It has proved particularly preferable to use air jet mills in which the material is comminuted by the impact of the particles on one another and on the walls of the grinding container. According to the invention, nitrogen is preferably used as the grinding gas. The material for grinding is conveyed by the grinding gas under specific pressures (grinding pressure). Within the scope of the present invention, the grinding pressure is usually set to a value between about 2 and 8 bar, preferably between about 3 and 7 bar, most preferably between about 3.5 and 6.5 bar. The material for grinding is fed into the air jet mill by means of the feed gas under specific pressures (feed pressure). Within the scope of the present invention a feed pressure of between about 2 and 8 bar, preferably between about 3 and 7 bar and most preferably between about 3.5 and 6 bar has proved satisfactory. The feed gas used is also preferably an inert gas, most preferably nitrogen again. The material to be ground (crystalline compound of formula 1) may be fed in at a rate of about 35 g/min, preferably at about 10-30 g/min.
For example, without restricting the subject of the invention thereto, the following apparatus has proved suitable as a possible embodiment of an air jet mill: a 2-inch Microniser with grinding ring, 0.8 mm bore, made by Messrs Sturtevant Inc., Circuit Street, Hanover, MA 02239, USA. Using this apparatus, the grinding process is preferably carried out with the following grinding parameters:
grinding pressure: about 4.5 - 6.5 bar; feed pressure: about 4.5 - 6.5 bar; supply of grinding material: about 17 - 21 g/min.
It may optionally be advantageous to add a finer excipient fraction with an average particle size of 1 to 9 m to the inhalable powders according to the invention.
Such inhalable powders which contain in addition to the active substance of formula I an excipient mixture which comprises, in addition to the excipient with an average particle size of 10 - 50 m mentioned hereinbefore, a specifically added excipient fraction with an average particle size of 1 - 9 m, are preferably prepared by first mixing the two excipient fractions and then adding the active substance to this excipient mixture. Suitable processes for preparing active substance formulations of this kind are known in the art (e.g. WO 02/30390, WO 03/017970, WO
03/017979).
If excipient mixtures of coarser and finer excipient fractions are used, the proportion of finer excipient in the total quantity of excipient is preferably 1 to 20%.
If excipient mixtures of coarser and finer excipient fractions are used, the coarser excipient fraction preferably has the above-mentioned properties in terms of mean particle size, specific surface area or crystallinity, whereas the finer excipient fraction mixed therewith is preferably characterised by an average particle size of from 2 to 8 m, particularly preferably from 3 to 7 m. Furthermore, the proportion of fine excipient fraction in the total quantity of excipient in inhalable powders of this kind which may be used is preferably 3 to 15%, particularly preferably 5 to 10%.
The present invention also relates to the use of the inhalable powders according to the invention for preparing a pharmaceutical composition for the treatment von respiratory complaints, particularly for the treatment of COPD and/or asthma.
The inhalable powders according to the invention may for example be administered by means of inhalers which deliver a single dose from a supply using a measuring chamber as described in US 4570630A, or by other means as described in DE 36 25 685 A.
Alternatively and of equivalent significance according to the invention, the inhalable powders according to the invention may also be administered using inhalers which contain the inhalable powder in a number of individually packaged doses (Pre-Metered Dry Powder Inhaler).
Alternatively and of equivalent significance according to the invention, the inhalable powders according to the invention may also be packaged in capsules which are administered in inhalers such as those described in WO 94/28958, for example.
Particularly preferably, the capsules containing the inhalable powder according to the invention are administered using an inhaler as shown in Figure 1.
This inhaler is characterised by a housing 1 containing two windows 2, a deck 3 in which there are air inlet ports and which is provided with a screen 5 secured via a screen housing 4, an inhalation chamber 6 connected to the deck 3 on which there is a push button 9 provided with two sharpened pins 7 and movable counter to a spring 8, and a mouthpiece 12 which is connected to the housing 1, the deck 3 and a cover 11 via a spindle 10 to enable it to be flipped open or shut, as well as air through-holes 13 for adjusting the flow resistance.
The present invention further relates to the use of the inhalable powders according to the invention for preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD and/or asthma, characterised in that the inhaler described above and shown in Figure 1 is used.
Capsules made of all kinds of materials may be used for administering the inhalable powders according to the invention by means of powder-filled capsules. By capsule material is meant, within the scope of the present invention, the material from which the shell of the capsule for inhalation is made. The capsule material is preferably selected according to the invention from among gelatine, cellulose derivatives, starch, starch derivatives, chitosan and synthetic plastics.
Alternatively and of equivalent significance according to the invention, the inhalable powders according to the invention may also be administered using inhalers which contain the inhalable powder in a number of individually packaged doses (Pre-Metered Dry Powder Inhaler).
Alternatively and of equivalent significance according to the invention, the inhalable powders according to the invention may also be packaged in capsules which are administered in inhalers such as those described in WO 94/28958, for example.
Particularly preferably, the capsules containing the inhalable powder according to the invention are administered using an inhaler as shown in Figure 1.
This inhaler is characterised by a housing 1 containing two windows 2, a deck 3 in which there are air inlet ports and which is provided with a screen 5 secured via a screen housing 4, an inhalation chamber 6 connected to the deck 3 on which there is a push button 9 provided with two sharpened pins 7 and movable counter to a spring 8, and a mouthpiece 12 which is connected to the housing 1, the deck 3 and a cover 11 via a spindle 10 to enable it to be flipped open or shut, as well as air through-holes 13 for adjusting the flow resistance.
The present invention further relates to the use of the inhalable powders according to the invention for preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD and/or asthma, characterised in that the inhaler described above and shown in Figure 1 is used.
Capsules made of all kinds of materials may be used for administering the inhalable powders according to the invention by means of powder-filled capsules. By capsule material is meant, within the scope of the present invention, the material from which the shell of the capsule for inhalation is made. The capsule material is preferably selected according to the invention from among gelatine, cellulose derivatives, starch, starch derivatives, chitosan and synthetic plastics.
If gelatine is used as the capsule material, it may be used in admixture with other additives selected from among polyethyleneglycol (PEG), preferably PEG 3350, glycerol, sorbitol, propyleneglycol, PEO-PPO block copolymers and other polyalcohols and polyethers. Within the scope of the present invention gelatine is used particularly preferably in admixture with PEG, preferably PEG 3350. A
gelatine capsule according to the invention preferably contains PEG in an amount of 1-10% (wt.-%), preferably 3-8 %. Particularly preferred gelatine capsules contain PEG in an amount of 4-6%, a PEG content of about 5 /% being most preferred according to the invention.
If cellulose derivatives are used as the capsule material, it is preferable to use hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxymethylcellulose and hydroxyethylcellulose. In this case, hydroxypropylmethylcellulose (HPMC), particularly preferably HPMC 2910 is used as the capsule material.
If synthetic plastics are used as the capsule material, these are preferably selected according to the invention from among polyethylene, polycarbonate, polyester, polypropylene and polyethylene terephthalate. Particularly preferred synthetic plastics are polyethylene, polycarbonate or polyethylene terephthalate. If polyethylene is used as one of the particularly preferred capsule materials according to the invention, polyethylene with a density of between 900 and 1000 kg/m3, preferably from 940 - 980 kg/m3 , particularly preferably 960-970 kg/m3 is preferably used (high-density polyethylene).
The synthetic plastics according to the invention may be processed in various ways using manufacturing methods known in the art. Processing of the plastics by injection moulding is preferred according to the invention. Injection moulding without the use of mould release agents is particularly preferred. This manufacturing method is well defined and is characterised by particularly good reproducibility.
In another aspect the present invention relates to the above-mentioned capsules containing the inhalable powder according to the invention as mentioned hereinbefore. These capsules may contain approximately 1 to 20 mg, preferably about 3 to 15, particularly preferably about 4 to 6 mg of inhalable powder.
gelatine capsule according to the invention preferably contains PEG in an amount of 1-10% (wt.-%), preferably 3-8 %. Particularly preferred gelatine capsules contain PEG in an amount of 4-6%, a PEG content of about 5 /% being most preferred according to the invention.
If cellulose derivatives are used as the capsule material, it is preferable to use hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxymethylcellulose and hydroxyethylcellulose. In this case, hydroxypropylmethylcellulose (HPMC), particularly preferably HPMC 2910 is used as the capsule material.
If synthetic plastics are used as the capsule material, these are preferably selected according to the invention from among polyethylene, polycarbonate, polyester, polypropylene and polyethylene terephthalate. Particularly preferred synthetic plastics are polyethylene, polycarbonate or polyethylene terephthalate. If polyethylene is used as one of the particularly preferred capsule materials according to the invention, polyethylene with a density of between 900 and 1000 kg/m3, preferably from 940 - 980 kg/m3 , particularly preferably 960-970 kg/m3 is preferably used (high-density polyethylene).
The synthetic plastics according to the invention may be processed in various ways using manufacturing methods known in the art. Processing of the plastics by injection moulding is preferred according to the invention. Injection moulding without the use of mould release agents is particularly preferred. This manufacturing method is well defined and is characterised by particularly good reproducibility.
In another aspect the present invention relates to the above-mentioned capsules containing the inhalable powder according to the invention as mentioned hereinbefore. These capsules may contain approximately 1 to 20 mg, preferably about 3 to 15, particularly preferably about 4 to 6 mg of inhalable powder.
The present invention also relates to an inhalation kit consisting of one or more of the above capsules characterised in that it contains inhalable powder according to the invention in conjunction with the inhaler according to Figure 1.
The present invention also relates to the use of the above-mentioned capsules characterised by their content of inhalable powder according to the invention, for preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD and/or asthma.
Filled capsules containing the inhalable powders according to the invention are produced by methods known in the art by filling the empty capsules with the inhalable powders according to the invention.
The following Examples serve to illustrate the present invention still further without restricting the scope of the invention to the following embodiments described by way of example.
Starting materials I) Excipient:
In the Examples that follow lactose-monohydrate is used as excipient. It may be obtained for example from Borculo Domo Ingredients, Borculo/NL under the product name Lactochem Extra Fine Powder. The specifications according to the invention for the particle size and specific surface area are met by this grade of lactose. In addition, this lactose has the above-mentioned preferred solution enthalpy values for lactose according to the invention.
II) Micronisation of the compound of formula 1 wherein X- denotes bromide:
The crystalline 2,2-diphenylpropionic acid scopine ester-methobromide which may be obtained according to WO 02/32899 (compound of formula 1 with X- _ bromide) is micronised with an air jet mill of the 2-inch microniser type with grinding ring, 0.8 mm bore, made by Messrs Sturtevant Inc., 348 Circuit Street, Hanover, MA 02239, USA. Using nitrogen as the grinding gas the following grinding parameters are set, for example:
grinding pressure: 5.5 bar; feed pressure: 5.5 bar; feed: 19 g/min.
The present invention also relates to the use of the above-mentioned capsules characterised by their content of inhalable powder according to the invention, for preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD and/or asthma.
Filled capsules containing the inhalable powders according to the invention are produced by methods known in the art by filling the empty capsules with the inhalable powders according to the invention.
The following Examples serve to illustrate the present invention still further without restricting the scope of the invention to the following embodiments described by way of example.
Starting materials I) Excipient:
In the Examples that follow lactose-monohydrate is used as excipient. It may be obtained for example from Borculo Domo Ingredients, Borculo/NL under the product name Lactochem Extra Fine Powder. The specifications according to the invention for the particle size and specific surface area are met by this grade of lactose. In addition, this lactose has the above-mentioned preferred solution enthalpy values for lactose according to the invention.
II) Micronisation of the compound of formula 1 wherein X- denotes bromide:
The crystalline 2,2-diphenylpropionic acid scopine ester-methobromide which may be obtained according to WO 02/32899 (compound of formula 1 with X- _ bromide) is micronised with an air jet mill of the 2-inch microniser type with grinding ring, 0.8 mm bore, made by Messrs Sturtevant Inc., 348 Circuit Street, Hanover, MA 02239, USA. Using nitrogen as the grinding gas the following grinding parameters are set, for example:
grinding pressure: 5.5 bar; feed pressure: 5.5 bar; feed: 19 g/min.
Measuring methods:
Determining the particle size of the micronised compound of formula 1 (X-= bromide):
Measuring equipment and settings:
The equipment is operated according to the manufacturer's instructions.
Measuring equipment: Laser-diffraction spectrometer (HELOS), SympaTec Dispersing unit: RODOS dry disperser with suction funnel, SympaTec Sample quantity: 200 mg 150 mg Product feed: Vibri Vibrating channel, Messrs. Sympatec Frequency of vibrating channel: rising to 100 %
Duration of sample feed: 15 to 25 sec. (in the case of 200 mg) Focal length: 100 mm (measuring range: 0.9 - 175 m) Measuring/waiting time: about 15 s (in the case of 200 mg) Cycle time: 20 ms Start/stop at: 1 % on channel 28 Dispersing gas: compressed air Pressure: 3 bar Vacuum: maximum Evaluation method: HRLD
Sample preparation /product feed:
About 200 mg of the test substance are weighed onto a piece of card.
Using another piece of card all the larger lumps are broken up. The powder is then sprinkled finely over the front half of the vibrating channel (starting about 1 cm from the front edge). After the start of the measurement the frequency of the vibrating channel is varied so that the sample is fed in as continuously as possible.
However, the quantity of product should not be too great either, so as to ensure adequate dispersal.
Determining the particle size of the micronised compound of formula 1 (X-= bromide):
Measuring equipment and settings:
The equipment is operated according to the manufacturer's instructions.
Measuring equipment: Laser-diffraction spectrometer (HELOS), SympaTec Dispersing unit: RODOS dry disperser with suction funnel, SympaTec Sample quantity: 200 mg 150 mg Product feed: Vibri Vibrating channel, Messrs. Sympatec Frequency of vibrating channel: rising to 100 %
Duration of sample feed: 15 to 25 sec. (in the case of 200 mg) Focal length: 100 mm (measuring range: 0.9 - 175 m) Measuring/waiting time: about 15 s (in the case of 200 mg) Cycle time: 20 ms Start/stop at: 1 % on channel 28 Dispersing gas: compressed air Pressure: 3 bar Vacuum: maximum Evaluation method: HRLD
Sample preparation /product feed:
About 200 mg of the test substance are weighed onto a piece of card.
Using another piece of card all the larger lumps are broken up. The powder is then sprinkled finely over the front half of the vibrating channel (starting about 1 cm from the front edge). After the start of the measurement the frequency of the vibrating channel is varied so that the sample is fed in as continuously as possible.
However, the quantity of product should not be too great either, so as to ensure adequate dispersal.
II) Determining the particle size of the lactose:
Measuring equipment and settings:
The equipment is operated according to the manufacturer's instructions.
Measuring equipment: Laser-diffraction spectrometer (HELOS), SympaTec Dispersing unit: RODOS dry disperser with suction funnel, (SympaTec) Sample quantity: 200 mg 100 mg Product feed: Vibri Vibrating channel, Messrs. Sympatec Frequency of vibrating channel: 100 % rising Focal length: 200 mm (measuring range: 1.8 - 350 gm) Measuring/waiting time: about 10 s (in the case of 200 mg) Cycle time: 10 ms Start/stop at: 1 % on channel 28 Dispersing gas: compressed air Pressure: 3 bar Vacuum: maximum Evaluation method: HRLD
Sample preparation /product feed:
About 200 mg of the test substance are weighed onto a piece of card.
Using another piece of card all the larger lumps are broken up. The powder is transferred into the vibrating channel. A gap of 1.2 to 1.4 mm is set between the vibrating channel and funnel. After the start of the measurement the frequency of the vibrating channel is increased as continuously as possible to 100 %
towards the end of the measurement.
III) Determining the specific surface area of the lactose (multi-point BET
method):
Method:
The specific surface is determined by exposing the powder sample to a nitrogen atmosphere at different pressures. Cooling the sample causes the nitrogen molecules to be condensed on the surface of the particles. The quantity of condensed nitrogen is determined by means of the drop in pressure in the system and the specific surface of the sample is calculated by means of the surface nitrogen requirement and the weight of the sample.
The equipment is operated according to the manufacturer's instructions.
Measuring equipment and settings:
Measuring equipment Tri Star Multi Point BET, Messrs Micromeritics Heater: VacPrep 061, Messrs. Micromeritics Heating: about 12h / 40 C
Sample tube: 1/2 inch; use filler rod Analysis Condition: 10 point BET surface 0.1 to 0.20 p/p0 Absolute P. tolerance: 5.0 mmHg rel. P. tolerance: 5.0 %
Evacuation rate: 50.0 mmHg/sec.
Unrestricted evac f.: 10.0 mmHg Evac. time: 0.1 hours Free Space: Lower Dewar, time: 0.5 h Equilibration interv. 20 sec Min. equl. delay: 600 sec Adsorptive: Nitrogen IV) Determining the heat of solution (enthalpy of solution) E.:
The solution enthalpy is determined using a solution calorimeter 2225 Precision Solution Calorimeter made by Messrs. Thermometric.
The heat of solution is calculated by means of the change in temperature occurring (as a result of the dissolving process) and the system-related change in temperature calculated from the base line. Before and after the ampoule is broken, electrical calibration is carried out with an integrated heating resistor of a precisely known power. A known heat output is delivered to the system over a set period and the jump in temperature is determined.
Method and equipment parameters:
Solution calorimeter: 2225 Precision Solution Calorimeter, Messrs Thermometric Reaction cell: 100 ml Thermistor resistance: 30.0 kf2 (at 25 C) Speed of stirrer: 500 U/min Thermostat: Thermostat of 2277 Thermal Activity Monitor TAM, Messrs Thermometric Temperature: 25 C 0.0001 C (over 24h) Measuring ampoules: Crushing ampoules 1 ml, Messrs Thermometric Seal: Silicon stopper and beeswax, Messrs. Thermometric Weight: 40 to 50 mg Solvent: Chemically pure water Volume of solvent: 100 ml Bath temperature: 25 C
Temperature resolution: High Starting temperature: -40mK ( 10mK) temperature-offset Interface: 2280-002 TAM accessory interface 50 Hz, Messrs Thermometric Software: SolCal V 1.1 for WINDOWS
Evaluation: Automatic evaluation with Menu point CALCULATION/
ANALYSE EXPERIMENT. (Dynamics of base line ;
calibration after breakage of ampoule).
Electrical calibration:
The electrical calibration takes place during the measurement, once before and once after the breakage of the ampoule. The calibration after the breakage of the ampoule is used for the evaluation.
Amount of heat: 2.5 J
Heating power: 500 mW
Heating time: 10 s Duration of base lines: 5 min (before and after heating) Preparation of the powder formulations according to the invention:
I) Apparatus The following machines and equipment, for example, may be used to prepare the inhalable powders:
Measuring equipment and settings:
The equipment is operated according to the manufacturer's instructions.
Measuring equipment: Laser-diffraction spectrometer (HELOS), SympaTec Dispersing unit: RODOS dry disperser with suction funnel, (SympaTec) Sample quantity: 200 mg 100 mg Product feed: Vibri Vibrating channel, Messrs. Sympatec Frequency of vibrating channel: 100 % rising Focal length: 200 mm (measuring range: 1.8 - 350 gm) Measuring/waiting time: about 10 s (in the case of 200 mg) Cycle time: 10 ms Start/stop at: 1 % on channel 28 Dispersing gas: compressed air Pressure: 3 bar Vacuum: maximum Evaluation method: HRLD
Sample preparation /product feed:
About 200 mg of the test substance are weighed onto a piece of card.
Using another piece of card all the larger lumps are broken up. The powder is transferred into the vibrating channel. A gap of 1.2 to 1.4 mm is set between the vibrating channel and funnel. After the start of the measurement the frequency of the vibrating channel is increased as continuously as possible to 100 %
towards the end of the measurement.
III) Determining the specific surface area of the lactose (multi-point BET
method):
Method:
The specific surface is determined by exposing the powder sample to a nitrogen atmosphere at different pressures. Cooling the sample causes the nitrogen molecules to be condensed on the surface of the particles. The quantity of condensed nitrogen is determined by means of the drop in pressure in the system and the specific surface of the sample is calculated by means of the surface nitrogen requirement and the weight of the sample.
The equipment is operated according to the manufacturer's instructions.
Measuring equipment and settings:
Measuring equipment Tri Star Multi Point BET, Messrs Micromeritics Heater: VacPrep 061, Messrs. Micromeritics Heating: about 12h / 40 C
Sample tube: 1/2 inch; use filler rod Analysis Condition: 10 point BET surface 0.1 to 0.20 p/p0 Absolute P. tolerance: 5.0 mmHg rel. P. tolerance: 5.0 %
Evacuation rate: 50.0 mmHg/sec.
Unrestricted evac f.: 10.0 mmHg Evac. time: 0.1 hours Free Space: Lower Dewar, time: 0.5 h Equilibration interv. 20 sec Min. equl. delay: 600 sec Adsorptive: Nitrogen IV) Determining the heat of solution (enthalpy of solution) E.:
The solution enthalpy is determined using a solution calorimeter 2225 Precision Solution Calorimeter made by Messrs. Thermometric.
The heat of solution is calculated by means of the change in temperature occurring (as a result of the dissolving process) and the system-related change in temperature calculated from the base line. Before and after the ampoule is broken, electrical calibration is carried out with an integrated heating resistor of a precisely known power. A known heat output is delivered to the system over a set period and the jump in temperature is determined.
Method and equipment parameters:
Solution calorimeter: 2225 Precision Solution Calorimeter, Messrs Thermometric Reaction cell: 100 ml Thermistor resistance: 30.0 kf2 (at 25 C) Speed of stirrer: 500 U/min Thermostat: Thermostat of 2277 Thermal Activity Monitor TAM, Messrs Thermometric Temperature: 25 C 0.0001 C (over 24h) Measuring ampoules: Crushing ampoules 1 ml, Messrs Thermometric Seal: Silicon stopper and beeswax, Messrs. Thermometric Weight: 40 to 50 mg Solvent: Chemically pure water Volume of solvent: 100 ml Bath temperature: 25 C
Temperature resolution: High Starting temperature: -40mK ( 10mK) temperature-offset Interface: 2280-002 TAM accessory interface 50 Hz, Messrs Thermometric Software: SolCal V 1.1 for WINDOWS
Evaluation: Automatic evaluation with Menu point CALCULATION/
ANALYSE EXPERIMENT. (Dynamics of base line ;
calibration after breakage of ampoule).
Electrical calibration:
The electrical calibration takes place during the measurement, once before and once after the breakage of the ampoule. The calibration after the breakage of the ampoule is used for the evaluation.
Amount of heat: 2.5 J
Heating power: 500 mW
Heating time: 10 s Duration of base lines: 5 min (before and after heating) Preparation of the powder formulations according to the invention:
I) Apparatus The following machines and equipment, for example, may be used to prepare the inhalable powders:
Mixing container or powder mixer: Turbulamischer 2 L, Type 2C; made by Willy A. Bachofen AG, CH-4500 Basel Hand-held screen: 0.135 mm mesh size The empty inhalation capsules may be filled with inhalable powders containing the active substance by hand or mechanically. The following equipment may be used.
Capsule filling machine:
MG2, Type G100, manufacturer: MG2 S.r.l, 1-40065 Pian di Macina di Pianoro (BO), Italy Example 1:
Powder mixture :
To prepare the powder mixture, 297.0 g of excipient and 3.0 g of micronised compound of formula 1 (wherein X- denotes bromide) are used. In the resulting 300 g of inhalable powder the content of active substance is 1 % (based on compound of formula 1 with X- = bromide). In terms of the pharmacologically active cation 1' this active substance content corresponds to a proportion of about 0.825%.
About 40-45 g of excipient are placed in a suitable mixing container through a hand-held screen with a mesh size of 0.315 mm. Then micronised compound of formula 1 (wherein X- denotes bromide) in batches of about 450-550 mg and excipient in batches of about 40-45 g are screened in in alternate layers. The excipient and active substance are added in 7 and 6 layers, respectively.
Having been screened in, the ingredients are then mixed (mixing speed 900 rpm).
The final mixture is passed twice more through a hand-held screen and then mixed again at 900 rpm.
Using the method described in Example 1 or analogously thereto, the following powders for inhalation may be obtained, for example:
Capsule filling machine:
MG2, Type G100, manufacturer: MG2 S.r.l, 1-40065 Pian di Macina di Pianoro (BO), Italy Example 1:
Powder mixture :
To prepare the powder mixture, 297.0 g of excipient and 3.0 g of micronised compound of formula 1 (wherein X- denotes bromide) are used. In the resulting 300 g of inhalable powder the content of active substance is 1 % (based on compound of formula 1 with X- = bromide). In terms of the pharmacologically active cation 1' this active substance content corresponds to a proportion of about 0.825%.
About 40-45 g of excipient are placed in a suitable mixing container through a hand-held screen with a mesh size of 0.315 mm. Then micronised compound of formula 1 (wherein X- denotes bromide) in batches of about 450-550 mg and excipient in batches of about 40-45 g are screened in in alternate layers. The excipient and active substance are added in 7 and 6 layers, respectively.
Having been screened in, the ingredients are then mixed (mixing speed 900 rpm).
The final mixture is passed twice more through a hand-held screen and then mixed again at 900 rpm.
Using the method described in Example 1 or analogously thereto, the following powders for inhalation may be obtained, for example:
Example 2:
active substance 1 (with X- = bromide) 3.000g lactose monohydrate*): 297.000g Total: 300.000g *> the excipient is characterised by the following parameters:
average particle size: 17.9 gm;
10% fine content: 2.3 gm;
specific surface area: 0.61 m2/g;
Example 3:
active substance 1 (with X- = bromide) 3.000g lactose monohydrate*): 297.000g Total: 300.000g the excipient is characterised by the following parameters:
average particle size: 18.5 m;
10% fine content: 2.2 gm;
specific surface area: 0.83 m2/g;
Example 4:
active substance 1 (with X- = bromide) 3.000g lactose monohydrate*): 297.000g Total: 300.000g *7 the excipient is characterised by the following parameters:
average particle size: 21,6 m;
10% fine content: 2.5 m;
specific surface area: 0.59 m2/g;
Example 5:
active substance 1 (with X- = bromide) 3.000g lactose monohydrate*): 297.000g Total: 300.000g the excipient is characterised by the following parameters:
average particle size: 16.0 m;
10% fine content: 2.0 m;
specific surface area: 0.79 m2/g;
active substance 1 (with X- = bromide) 3.000g lactose monohydrate*): 297.000g Total: 300.000g *> the excipient is characterised by the following parameters:
average particle size: 17.9 gm;
10% fine content: 2.3 gm;
specific surface area: 0.61 m2/g;
Example 3:
active substance 1 (with X- = bromide) 3.000g lactose monohydrate*): 297.000g Total: 300.000g the excipient is characterised by the following parameters:
average particle size: 18.5 m;
10% fine content: 2.2 gm;
specific surface area: 0.83 m2/g;
Example 4:
active substance 1 (with X- = bromide) 3.000g lactose monohydrate*): 297.000g Total: 300.000g *7 the excipient is characterised by the following parameters:
average particle size: 21,6 m;
10% fine content: 2.5 m;
specific surface area: 0.59 m2/g;
Example 5:
active substance 1 (with X- = bromide) 3.000g lactose monohydrate*): 297.000g Total: 300.000g the excipient is characterised by the following parameters:
average particle size: 16.0 m;
10% fine content: 2.0 m;
specific surface area: 0.79 m2/g;
Example 6:
active substance 1 (with X- = bromide) 6.000g lactose monohydrate*): 294.000g Total: 300.000g *> the excipient is characterised by the following parameters:
average particle size: 17,9 m;
10% fine content: 2.3 m;
specific surface area: 0.61 m2/g;
Example 7:
active substance 1 (with X- = bromide) 6.000g lactose monohydrate*): 294.000g Total: 300.000g the excipient is characterised by the following parameters:
average particle size: 18.5 m;
10% fine content: 2.2 m;
specific surface area: 0.83 m2/g;
Example 8:
active substance 1 (with X- = bromide) 1. 500g lactose monohydrate*): 298.500g Total: 300.000g the excipient is characterised by the following parameters:
average particle size: 17.9 gm;
10% fine content: 2.3 m;
specific surface area: 0.61 m2/g;
Example 9:
active substance 1 (with X- = bromide) 1.500g lactose monohydrate*): 298.500g Total: 300.000g the excipient is characterised by the following parameters:
average particle size: 18.5 m;
10% fine content: 2.2 m;
specific surface area: 0.83 m2/g;
active substance 1 (with X- = bromide) 6.000g lactose monohydrate*): 294.000g Total: 300.000g *> the excipient is characterised by the following parameters:
average particle size: 17,9 m;
10% fine content: 2.3 m;
specific surface area: 0.61 m2/g;
Example 7:
active substance 1 (with X- = bromide) 6.000g lactose monohydrate*): 294.000g Total: 300.000g the excipient is characterised by the following parameters:
average particle size: 18.5 m;
10% fine content: 2.2 m;
specific surface area: 0.83 m2/g;
Example 8:
active substance 1 (with X- = bromide) 1. 500g lactose monohydrate*): 298.500g Total: 300.000g the excipient is characterised by the following parameters:
average particle size: 17.9 gm;
10% fine content: 2.3 m;
specific surface area: 0.61 m2/g;
Example 9:
active substance 1 (with X- = bromide) 1.500g lactose monohydrate*): 298.500g Total: 300.000g the excipient is characterised by the following parameters:
average particle size: 18.5 m;
10% fine content: 2.2 m;
specific surface area: 0.83 m2/g;
Example 10:
active substance 1 (with X- = bromide) 6.000g dextrose monohydrate*): 294.000g Total: 300.000g *) the excipient is characterised by the following parameters:
average particle size: 18.5 m;
10`! fine content: 2.2 m;
Example 11:
active substance 1 (with X- = bromide) 1.500g dextrose monohydrate*): 298.500g Total: 300.000g the excipient is characterised by the following parameters:
average particle size: 17.9 m;
10% fine content: 2.3 m;
Example 12:
active substance 1 (with X- = bromide) 3.000g dextrose monohydrate*): 297.000g Total: 300.000g *> the excipient is characterised by the following parameters:
average particle size: 18.5 m;
10% fine content: 2.2 m;
The formulations in the above Examples may be packed in appropriate amounts into suitable packaging means, e.g. polyethylene capsules, or may be used directly in multi-dose powder inhalers.
active substance 1 (with X- = bromide) 6.000g dextrose monohydrate*): 294.000g Total: 300.000g *) the excipient is characterised by the following parameters:
average particle size: 18.5 m;
10`! fine content: 2.2 m;
Example 11:
active substance 1 (with X- = bromide) 1.500g dextrose monohydrate*): 298.500g Total: 300.000g the excipient is characterised by the following parameters:
average particle size: 17.9 m;
10% fine content: 2.3 m;
Example 12:
active substance 1 (with X- = bromide) 3.000g dextrose monohydrate*): 297.000g Total: 300.000g *> the excipient is characterised by the following parameters:
average particle size: 18.5 m;
10% fine content: 2.2 m;
The formulations in the above Examples may be packed in appropriate amounts into suitable packaging means, e.g. polyethylene capsules, or may be used directly in multi-dose powder inhalers.
Claims (11)
1. Inhalable powder, containing as sole active substance a hydrate of the compound of formula 1 wherein X- denotes a pharmaceutically acceptable anion, in admixture with a physiologically acceptable excipient, wherein the excipient has an average particle size of 12 - 35 µm and the excipient has a 10% fine content of 0.5 to 6 µm.
2. Inhalable powder according to claim 1, wherein the anion X- is selected from the group consisting of chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulphonate.
3. Inhalable powder according to claim 1 or 2, wherein the content of active substance based on the pharmacologically active cation of formula 1' is between 0.0008 and 33 %.
4. Inhalable powder according to claim 1, 2 or 3, wherein the physiologically acceptable excipient is selected from the group consisting of monosaccharides, disaccharides, oligo- and polysaccharides, polyalcohols, cyclodextrins, amino acids and the salts thereof.
5. Inhalable powder according to any one of claims 1 to 4, wherein the excipient has a specific surface area of 0.1 to 2 m2/g.
6. Use of an inhalable powder according to any one of claims 1 to 5 for preparing a pharmaceutical composition for the treatment of a respiratory complaint.
7. The use of an inhalable powder according to claim 6 for preparing a pharmaceutical composition for the treatment of a respiratory complaint, wherein the respiratory complaint is either chronic obstructive pulmonary disease (COPD) or asthma.
8. Capsule containing an inhalable powder according to any one of claims 1 to 5.
9. Capsule according to claim 8, wherein the capsule material consists of synthetic plastics.
10. Inhalation kit consisting of a capsule according to claim 8 or 9 and an inhaler which may be used for administering inhalable powders from powder-filled capsules.
11. Inhalation kit according to claim 10, wherein the inhaler comprises a housing containing two windows, a deck in which there are air inlet ports and which is provided with a screen secured via a screen housing, an inhalation chamber connected to the deck on which there is a push button provided with two sharpened pins and movable counter to a spring, and a mouthpiece which is connected to the housing, the deck and a cover via a spindle to enable it to be flipped open or shut, as well as air through-holes for adjusting the flow resistance.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10331350A DE10331350A1 (en) | 2003-07-11 | 2003-07-11 | Inhalation powder useful for treating respiratory diseases comprises a 9,9-dimethyl-7-(2,2-diphenylpropionyloxy)-3-oxa-9-azatricyclononane salt and a finely divided excipient |
| DE10331350.8 | 2003-07-11 | ||
| PCT/EP2004/007357 WO2005007134A1 (en) | 2003-07-11 | 2004-07-06 | Powdery formulations for inhalation, containing a novel anticholinergic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2531832A1 CA2531832A1 (en) | 2005-01-27 |
| CA2531832C true CA2531832C (en) | 2012-09-18 |
Family
ID=33546971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2531832A Expired - Lifetime CA2531832C (en) | 2003-07-11 | 2004-07-06 | Powdery formulations for inhalation, containing a novel anticholinergic agent |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1646365B1 (en) |
| JP (1) | JP2009514778A (en) |
| AT (1) | ATE420627T1 (en) |
| CA (1) | CA2531832C (en) |
| DE (2) | DE10331350A1 (en) |
| ES (1) | ES2318298T3 (en) |
| WO (1) | WO2005007134A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1925296A1 (en) * | 2006-11-22 | 2008-05-28 | Boehringer Ingelheim Pharma GmbH & Co. KG | Stable powder formulation containing a new antichinolinergic agent |
| EP1925295A1 (en) * | 2006-11-22 | 2008-05-28 | Boehringer Ingelheim Pharma GmbH & Co. KG | Stable powder formulation containing a new antichinolinergic agent |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA75375C2 (en) * | 2000-10-12 | 2006-04-17 | Boehringer Ingelheim Pharma | Method for producing powdery preparations for inhaling |
| DE10050994A1 (en) * | 2000-10-14 | 2002-04-18 | Boehringer Ingelheim Pharma | New diphenylalkanoic acid azabicyclooctane ester quaternary salts useful as anticholinergic agents, especially in treatment of asthma and chronic obstructive pulmonary disease |
-
2003
- 2003-07-11 DE DE10331350A patent/DE10331350A1/en not_active Withdrawn
-
2004
- 2004-07-06 JP JP2006518121A patent/JP2009514778A/en active Pending
- 2004-07-06 CA CA2531832A patent/CA2531832C/en not_active Expired - Lifetime
- 2004-07-06 EP EP04740685A patent/EP1646365B1/en not_active Expired - Lifetime
- 2004-07-06 DE DE502004008877T patent/DE502004008877D1/en not_active Expired - Lifetime
- 2004-07-06 WO PCT/EP2004/007357 patent/WO2005007134A1/en active Application Filing
- 2004-07-06 AT AT04740685T patent/ATE420627T1/en active
- 2004-07-06 ES ES04740685T patent/ES2318298T3/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005007134A8 (en) | 2006-06-15 |
| WO2005007134A1 (en) | 2005-01-27 |
| ATE420627T1 (en) | 2009-01-15 |
| JP2009514778A (en) | 2009-04-09 |
| EP1646365B1 (en) | 2009-01-14 |
| ES2318298T3 (en) | 2009-05-01 |
| DE10331350A1 (en) | 2005-01-27 |
| DE502004008877D1 (en) | 2009-03-05 |
| EP1646365A1 (en) | 2006-04-19 |
| CA2531832A1 (en) | 2005-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7462367B2 (en) | Anticholinergic powder formulations for inhalation | |
| US8197845B2 (en) | Encapsulated tiotropium containing powder formulation for inhalation | |
| CA2395653C (en) | New inhalable powder containing tiotropium | |
| AU2003288226B2 (en) | Powdered medicament for inhalation comprising a tiotropium salt and salmeterol xinafoate | |
| AU2008203057C8 (en) | Inhalation capsules | |
| US20070031347A1 (en) | Powdered Medicaments Containing A Tiotropium Salt and Salmeterol Xinafoate | |
| BG66194B1 (en) | Method for producing powdery formulations | |
| US20050084457A1 (en) | Capsules containing inhalable tiotropium | |
| AU2003294714B2 (en) | Pulverulent formulation for inhalation containing tiotropium | |
| CA2531832C (en) | Powdery formulations for inhalation, containing a novel anticholinergic agent | |
| NZ540844A (en) | Pulverulent formulation for inhalation containing tiotropium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |